

Liver disease in the era of COVID-19: Is the worst yet to come?

Mikolašević, Ivana; Božić, Dorotea; Pavić, Tajana; Ružić, Alen; Hauser, Goran; Radić, Marija; Radić-Krisšo, Delfa; Ražov-Radas, Melanija; Puljiz, Željko; Milić, Sandra

Source / Izvornik: **World Journal of Gastroenterology, 2021, 27, 6039 - 6052**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3748/wjg.v27.i36.6039>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:335647>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2025-02-18**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



Liver disease in the era of COVID-19: Is the worst yet to come?

Ivana Mikolasevic, Dorotea Bozic, Tajana Pavić, Alen Ruzic, Goran Hauser, Marija Radic, Delfa Radic-Kristo, Melanija Razov-Radas, Zeljko Puljiz, Sandra Milic

ORCID number: Ivana Mikolasevic 0000-0001-9676-0642; Dorotea Bozic 0000-0001-9234-4203; Tajana Pavić 0000-0002-0370-5001; Alen Ruzic 0000-0001-5031-2975; Goran Hauser 0000-0002-4758-1717; Marija Radic 0000-0002-7746-2065; Delfa Radic-Kristo 0000-0002-2827-7808; Melanija Razov-Radas 0000-0003-4530-4350; Zeljko Puljiz 0000-0002-3465-4227; Sandra Milic 0000-0002-6635-5360.

Author contributions: Mikolasevic I researched the database, wrote the manuscript and is the guarantor of this work; Bozic D, Pavić T, Ruzic A, Hauser G, Milic S, Radic M, Radic-Kristo D, Razov-Radas M and Puljiz Z contributed to the discussion and reviewed/edited the manuscript.

Conflict-of-interest statement: Authors declare no conflict of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and

Ivana Mikolasevic, Goran Hauser, Sandra Milic, Department of Gastroenterology, Clinical Hospital Center Rijeka, Rijeka 51000, Croatia

Ivana Mikolasevic, Department of Gastroenterology, University Hospital Merkur, Zagreb 10000, Croatia

Ivana Mikolasevic, Alen Ruzic, Goran Hauser, Sandra Milic, Faculty of Medicine, University of Rijeka, Rijeka 51000, Croatia

Dorotea Bozic, Zeljko Puljiz, Department for Gastroenterology and Hepatology, University Hospital Center Split, Split 21000, Croatia

Tajana Pavić, Department of Gastroenterology and Hepatology, Faculty of Medicine, Sestre Milosrdnice University Hospital Center, Zagreb 10000, Croatia

Alen Ruzic, Clinic for Cardiology, University Hospital Center Rijeka, Rijeka 51000, Croatia

Goran Hauser, Faculty of Health Studies, University of Rijeka, Rijeka 51000, Croatia

Marija Radic, Delfa Radic-Kristo, Faculty of Medicine, Zagreb 10000, Croatia

Delfa Radic-Kristo, Department of Hematology, University Hospital Merkur, Zagreb 10000, Croatia

Melanija Razov-Radas, Division of Gastroenterology, General Hospital Zadar, Zadar 23000, Croatia

Zeljko Puljiz, University of Split, School of Medicine, Split 21000, Croatia

Corresponding author: Ivana Mikolasevic, PhD, Professor, Department of Gastroenterology, Clinical Hospital Center Rijeka, Kresimirova 42, Rijeka 51000, Croatia.
ivana.mikolasevic@gmail.com

Abstract

The global social, economic and political crises related to coronavirus disease 2019 (COVID-19) presumably had more indirect than direct negative impacts on health systems. Drastic lifestyle changes, social isolation and distancing, and individual and global financial crises resulted in robust populations forfeiting healthy habits and seeking comfort in alcoholic beverages, drugs and unhealthy diets. The inevitable consequences are increases in the incidence of nonalcoholic fatty liver disease, viral hepatitis, acute alcoholic hepatitis, liver cirrhosis decompensation

the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: Croatia

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

Received: February 28, 2021

Peer-review started: February 28, 2021

First decision: July 3, 2021

Revised: July 18, 2021

Accepted: September 1, 2021

Article in press: September 1, 2021

Published online: September 28, 2021

P-Reviewer: Ferraioli G, Gupta MK, Skok K

S-Editor: Gao CC

L-Editor: A

P-Editor: Yuan YY



and ultimately liver-related mortality. The inaccessibility of regular clinical and sonographic monitoring systems has caused difficulties in the treatment of patients with chronic liver disease (CLD) and has prevented prompt hepatocellular carcinoma detection and treatment. A dramatic reduction in the number of liver donors and the transformation of numerous transplantation centers into COVID-19 units drastically decreased the rate of orthotopic liver transplantation. The indirect, unavoidable effects of the COVID-19 pandemic in the following years have yet to be determined. Substantial efforts in the management of patients with liver disease in order to overcome the inevitable COVID-19-related morbidity and mortality that will follow have yet to be initiated. Several questions regarding the impact of the COVID-19 pandemic on liver disease remain. The most important question for general CLD patients is: How will the modification of clinical practice during this pandemic affect the outcomes of CLD patients? This article reviews the influence of COVID-19 on patients with liver disease during the pandemic, with particular emphasis on the disease course associated with pandemic resolution.

Key Words: COVID-19; Pandemic; Chronic liver disease; Management; Impact; Liver-related mortality

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The global social, economic and political crises related to coronavirus disease 2019 (COVID-19) presumably cause more indirect than direct negative impacts on the health system. Drastic lifestyle changes, social isolation and distancing, and individual and global financial crises resulted in a robust population forfeiting healthy habits and seeking comfort in alcoholic beverages, drugs and unhealthy diets. The inevitable consequence is the increasing incidence of liver disease, liver cirrhosis decompensation and ultimately liver-related mortality. The indirect unavoidable effects of the COVID-19 pandemic in the following years have yet to be determined.

Citation: Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? *World J Gastroenterol* 2021; 27(36): 6039-6052

URL: <https://www.wjgnet.com/1007-9327/full/v27/i36/6039.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v27.i36.6039>

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide and poses a serious threat to healthcare systems globally. It is common to encounter patients with both COVID-19 and abnormal liver function. Because COVID-19 is a newly discovered disease, additional data are needed to improve our understanding of its impact on the liver and of the appropriate management of such patients[1-15]. Information on how COVID-19 infection affects the liver and the relevance of pre-existing liver disease in acquiring the infection or developing severe disease is increasing, although we still do not know the exact mechanism. Additionally, considerations with regard to liver transplant patients, those with hepatocellular carcinoma (HCC) and those under immunosuppressive therapy are being analyzed as information is being generated. Various treatments for COVID-19 are currently under study but some of these may be potentially hepatotoxic[4-6,15].

The first and most evident consequence of the COVID-19 pandemic is its impact on the routine care of patients with chronic liver disease (CLD). The COVID-19 pandemic shifted our perception of ambulatory patient care from face-to-face examinations to virtual patient management[15-18]. Expert recommendations guiding clinicians in the treatment of patients with CLD and of transplanted patients during the pandemic are available in the form of guidelines published by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver

Diseases (AASLD)[16-18].

Although patients with CLD are not at higher risk of acquiring the infection, whether COVID-19 and the underlying liver disease will follow an unfavorable course remains to be answered[19]. Nonetheless, questions regarding the treatment of patients with CLD following resolution of the COVID-19 pandemic remain unknown. One must consider that a considerable number of patients with CLD did not attend regular appointments, prevented by fear of acquiring the infection. Preventive, surgical and transplant programs have become secondary focuses. In light of the present circumstances, it is evident that the burdens of the pandemic-related consequences have yet to be elucidated, not only regarding global economics but also global health[19].

This article reviews the effects of COVID-19 in patients with liver disease during the pandemic, with particular emphasis on the disease course associated with pandemic resolution (Figure 1). We performed a PubMed search using the keywords “chronic liver disease” and “COVID-19”. When using this algorithm there were 396 results. In this review, 74 articles with particular emphasis on COVID-19 and liver disease were analyzed.

PRE-EXISTING CLD AND COVID-19

The reported prevalence of patients with CLD in cohorts of patients with COVID-19 does not exceed 1%, suggesting that the risk of infection acquisition is similar to that in the general population[18,20]. However, the risk of a severe course of disease might be increased due to the etiology of the underlying liver disease along with the degree of liver fibrosis[18].

Liver test abnormalities

According to reports from regular and intensive care units, elevated liver enzymes, lactate dehydrogenase, creatinine kinase and myoglobin, as well as prolonged prothrombin time, are found in more than one-third of patients during COVID-19 progression[21]. A retrospective Chinese study revealed a dynamic pattern of liver molecules regardless of the severity of infection: Aspartate aminotransferase (AST) increased, followed by an increase in alanine aminotransferase (ALT) concurrent with mild oscillations in bilirubin levels. AST levels were significantly associated with mortality risk in this group of patients[22]. Another comprehensive Chinese review also reported elevated AST and ALT levels in 6%-22% and 21%-28% of patients, respectively[23]. Compared to other Chinese regions in which 16% of patients had AST elevation, studies from Wuhan reported a higher percentage, ranging from 24% to 37%. Studies have revealed a high prevalence of liver test abnormalities in men and elderly individuals[23,24]. A large American study including 5700 patients reported that 58.4% of patients had elevated AST levels (> 40 U/L) and 39% had elevated ALT levels (> 60 U/L)[25]. Two percent of patients developed acute hepatic injury and the majority of this subgroup (95%) did not survive[25]. A severe cholestatic pattern has not been reported as correlating with COVID-19 but studies have reported hyperbilirubinemia in 11%-18% of cases[21].

Several pathological mechanisms are considered to be involved in liver injury, including direct viral infection of liver cells, drug hepatotoxicity, cytokine storm and pneumonia-associated hypoxia[15,26,27]. According to several studies, the expression of ACE2 receptors on liver cells facilitates SARS CoV-2 entrance; expression is increased in bile duct cells, whose destruction appears to be primarily responsible for COVID-19-related liver injury[15,26]. Studies clarifying the exact mechanisms of liver injury are warranted[15,27-30].

It must be considered that elevated aminotransferases might be of cardiac or muscular origin and that abnormalities in liver tests are frequently transient. On the other hand, studies have reported an increased risk of severe disease in patients who present with liver injury on admission[15,28]. The severity of liver dysfunction seems to be closely associated with the severity of COVID-19[15]. As predicted by multiple studies, the usual culprits of pathological biochemical liver abnormalities are underlying CLD, sepsis-related cholestasis and drug hepatotoxicity[6]. We must not ignore the fact that the frequency and severity of liver injury in asymptomatic individuals and patients under out-of-hospital treatment remains unknown[6]. Therefore, further investigations are needed to strengthen conclusions.

Finally, the most crucial question for clinicians treating COVID-19 patients is in whom and how often to perform liver function tests. The optimal interval has not yet




Figure 1 Global and individual effects of the coronavirus disease 2019 pandemic on liver-related morbidity and mortality. ACLF: Acute-on-chronic liver failure; AH: Arterial hypertension; ASH: Alcoholic steatohepatitis; CLD: Chronic liver disease; COVID-19: Coronavirus disease 2019; DILI: Drug-induced liver injury; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; OLT: Orthotopic liver transplantation.

been defined, but physicians should certainly be attentive when treating severely ill patients and individuals taking novel antiviral drugs such as remdesivir or tocilizumab[6].

Nonalcoholic fatty liver disease and COVID-19

Nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated fatty liver disease, is a common manifestation of metabolic syndrome and is remarkably prevalent in Western industrialized countries[21]. It is usually comorbid with obesity, which represents a significant risk factor for severe COVID-19 pneumonia[3,18,31]. The assumed mechanism relies on the immunological properties of adipose tissue, which also plays a role as a viral reservoir[3,18,25]. Additional risk factors accompanying NAFLD, such as arterial hypertension, obesity and diabetes, are also commonly observed in patients with a severe COVID-19 course[3,18,25].

As predicted in several studies, patients with NAFLD seem to have a longer period of viral replication and dispersion[32] and experience progression to the severe form of disease, with worsening dyspnea, hypoxia and typical radiological findings [32], even in younger patients without other comorbidities[33,34]. Among patients with NAFLD, the underlying liver fibrosis seems to correlate with severe COVID-19 presentation, regardless of other metabolic comorbidities[11,21,35]. Targher *et al*[35] also found an interrelation between advanced liver fibrosis (defined as increased Fibrosis 4 and NAFLD fibrosis scores) and severe COVID-19 presentation in a subgroup of 94 (30.3%) patients with NAFLD. However, Lopez-Mendez *et al*[36] did not confirm these findings. According to their study, although the prevalence of NAFLD and significant liver fibrosis was high in COVID-19 patients, it was not associated with worse clinical outcomes.

The exact mechanism of NAFLD-associated liver fibrosis leading to an undesired COVID-19 course has not yet been defined but presumably is potentiated by the hepatic release of multiple proinflammatory cytokines, exacerbating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cytokine storm[35]. On the other hand, virus-related cytokines might increase the risk of liver inflammation. This interplay of cytokine-related events forms a vicious cycle, making the NAFLD population at very high risk of COVID-19 complications[11,21].

Additional large-scale analyses are needed to determine whether NAFLD is an independent risk factor for severe COVID-19 or whether confounding factors are responsible for the previously published results. Studies based on other available noninvasive methods, including transient elastography and acoustic radiation force impulse-based techniques, are also warranted.

It is also important to note the increased predisposition for drug-induced liver injury in patients with liver steatosis[6]. Antiretrovirals such as lopinavir/ritonavir, antibiotics, antifungal agents and other drugs required to treat acute respiratory distress syndrome and systemic inflammation may induce drug-induced liver injury [37]. The possible mechanism of increased susceptibility in this group of patients is associated with oxidative stress, diminished activity of xenobiotic-metabolizing enzymes, mitochondrial malfunction and changes in lipid homeostasis[37-39]. Caution must be taken with steatogenic drugs such as amiodarone, sodium valproate, tamoxifen, methotrexate and frequently used glucocorticoids because they may induce steatohepatitis in predisposed individuals[40].

Finally, the effect of the COVID-19 pandemic on the social aspects of an individual's daily routine is the last but not least important undesirable sequela. A sedentary lifestyle, social isolation and increased consumption of processed foods are all metabolic antagonists that are especially unfavorable in patients with NAFLD[18]. The COVID-19 "blues" associated with lockdowns, loss of income and deterioration of socioeconomic status might lead to unhealthy lifestyles and consequently the promotion of obesity and associated metabolic diseases[41]. Therefore, COVID-19 will presumably be an indirect cause of expansion of the NAFLD epidemic[42]. In light of the global psychosociological COVID-19 burden, the Mayo Clinic advocates increased caution against NAFLD-promoting behaviors[42,43].

Increases in body mass index uncontrollable arterial hypertension and underregulated diabetes will certainly contribute to the worsening of NAFLD. It is therefore mandatory to treat associated metabolic comorbidities in these patients[18]. In addition, the deleterious effects of delayed detection of HCC in hepatic steatosis patients are the consequences of missed routine ultrasound examinations.

In conclusion, the EASL suggests considering early admission for all patients with NAFLD and COVID-19[18]. Encouraged by the AASLD guidelines, we recommend regular monitoring of liver function in all hospitalized COVID-19 patients[17,21]. Governments and policy makers should implement certain interventions in response to the increase in NAFLD that will insidiously follow after the COVID-19 pandemic [41]. Finally, when contemplating the introduction of lockdown in the future, the potential consequences on metabolic health should be considered[41].

Autoimmune liver disease and COVID-19

Evidence of the influence of immunosuppressive regimens on the acquisition of COVID-19 is still scarce. However, observational studies have suggested an association between glucocorticoid therapy and a severe COVID-19 course[18,44]. When treating autoimmune hepatitis (AIH) flares, the EASL suggests the administration of budesonide rather than systemic corticosteroid therapy in patients without liver cirrhosis[18]. In the clinical setting of a chronic immunosuppressive regimen it is recommended to continue treatment, except in cases of severe COVID-19, superinfections or lymphopenia that frequently follow SARS-CoV-2 infection[16]. According to the largest study of patients with AIH and COVID-19 infection there were no significant differences in the incidence of major adverse COVID-19 outcomes between patients with AIH and those with other CLD[10]. However, in this study, independent risk factors for adverse events (*i.e.*, death) in these patients were age and baseline liver disease severity. In this study, the use of immunosuppression was not associated with death in AIH patients[10]. Additional studies are needed to determine whether AIH per se or adjacent immunosuppressive treatment affect COVID-19 outcomes[18].

Alcoholic liver disease and COVID-19

Patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) are exemplars of the wide range of potentially negative impacts of COVID-19[45]. Primarily, social isolation and the unavailability of professional help may lead to psychological decompensation and an increased risk of relapse[45]. Depressed immune systems and other underlying comorbidities, including renal failure, obesity, chronic viral hepatitis, sarcopenia, alcoholic cardiomyopathy, tobacco use disorder and many others, make these patients easy targets for viral infection. Finally, according to published data, these patients are more prone to developing interstitial pneumonia and acute respiratory distress syndrome secondary to SARS-CoV-2 infection than their counterparts[18]. Case series of ALD individuals reported a rapid disease course, including bilobar pneumonia and acute respiratory distress syndrome requiring mechanical ventilation, with unfavorable outcomes including cardiopulmonary insufficiency and multiorgan failure[46,47]. Patients admitted for acute alcoholic steatohepatitis (ASH) are usually assessed using Maddrey's discriminant function (DF) score, with DF > 32 predicting a higher mortality rate[46]. The usual

treatment of ASH in patients with DF > 32 using the classical prednisone regimen is an additional risk factor for a severe course of COVID-19 and is therefore not recommended for patients who are self-isolating or considered at high risk of acquiring SARS-CoV-2 infection[45]. Liver impairment is frequently observed in patients with COVID-19[46]. It is also well known that ASH increases the risk of hepatorenal syndrome development, especially after contrast agent application. Cytokine damage, inadequate organ perfusion, nephrotoxic drug effects and nosocomial infections all potentiate the acute kidney injury, usually resulting in the need for continuous renal replacement therapy[47].

In order to obviate the described critical disease course with severe consequences and high mortality rate, we should focus on two main aspects in the care of ALD patients. The primary focus is the prevention, of infection by following strict epidemiologic recommendations, as well as the prevention of AUD relapse by implementing vigorous social and psychiatric care by telephone. The unavailability of support groups such as Alcoholics Anonymous should be bridged using individual or smaller group treatment[47]. The secondary focus is the prevention of a deleterious disease course using vigilant intrahospital clinical care and timely recognition of hepatobiliary, renal and respiratory complications[18].

Viral hepatitis and COVID-19

Whether chronic viral hepatitis specifically affects the COVID-19 course remains unknown. In a retrospective Italian multicenter study that included 50 patients with liver cirrhosis and SARS-CoV-2 infection, 28% had hepatitis C virus (HCV)-related cirrhosis and 10% had hepatitis B virus (HBV)-related cirrhosis. The patients were either HCV-RNA negative after anti-HCV treatment or on long-term anti-HBV treatment. The severity of liver disease was an independent predictor of mortality[29]. The same conclusion was derived from an international registry that included 152 patients with CLD and COVID-19, among which 22.5% of the CLD was due to chronic HBV or HCV infection[30].

In the last year, the COVID-19 outbreak has redirected attention from other morbidities, including viral hepatitis: as a consequence of this pandemic, most viral hepatitis elimination programs have diminished or stopped altogether[14,19,48,49]. The World Health Organization's goal of eliminating HBV and HCV and thus significantly reducing the associated mortality until 2030 has therefore been put on hold. Elimination programs are already scarce, as well as involvement by liver disease societies, epidemiologists, infection specialists and general practitioners, despite the WHO Global Hepatitis Report 2017 stating that the viral hepatitis global mortality is 1.5 million per year[19,48,49]. Preventing mother-to-child transmission and promoting blood safety are presumably the only intact weapons in the battle against HBV and HCV[19,48]. Although we will realize the full impact of reducing or delaying programs targeting hepatitis elimination in the near future, there are some mathematical models that can predict the possible impact on the global burden of viral hepatitis and hepatitis-associated morbidity and mortality that will result as a consequence of program delay[49]. A recent study used certain mathematical models to analyze the impact of delayed programs on viral hepatitis elimination[49]. The authors reported that a 1-year delay in viral hepatitis diagnosis and treatment will result in an additional 44800 HCC cases as well as 72300 deaths from HCV globally in the next 10 years[49].

If we cannot make progress in achieving the aforementioned elimination goals due to the COVID-19 crisis, then education campaigns, extensive screening, diagnostic tests, vaccination programs and treatment should at least be maintained at the former level[19,48,49].

Liver cirrhosis and COVID-19

Patients with liver cirrhosis, particularly decompensated cirrhosis, are by far the most vulnerable liver disease patients. Immune dysfunction makes them prone to any kind of infection, including SARS-CoV-2, with potentially deleterious effects on the disease course. Data suggest that the course of COVID-19 is directly connected to the degree of liver disease defined by the Child-Pugh (CP) and Model for End Stage Liver Disease scores[18].

An international registry including 103 patients with liver cirrhosis reported a 40% mortality rate, strongly correlated with the grade of liver failure: 23.9% mortality in patients with CP class A, 43.3% mortality in patients with CP class B and 63.0% mortality in patients with CP class C cirrhosis[50]. Similarly, an Italian study involving 50 patients with liver cirrhosis suffering from COVID-19 found a 30-d mortality rate of 34%, among which 71% of patients died due to COVID-related respiratory failure[51].

The largest published study to date was based on two international registries and included 745 patients with CLD (among which 52% had liver cirrhosis) and acute COVID-19 infection. When compared to the data of non-CLD patients with SARS-CoV-2 infection in a UK hospital network, a statistically significant difference in mortality ($P < 0.001$) was reported: 32% in patients with liver cirrhosis compared to 8% in those without[52]. The main cause of death was respiratory failure, with acute decompensation of liver cirrhosis occurring in 46% of patients. The authors concluded that the CP score and ALD were independent risk factors for death due to COVID-19 [52].

A prospective American multicenter study by Singh and Khan[53] compared patients with both liver cirrhosis and COVID-19 to patients with only COVID-19 and found a significant difference in the outcome (30% *vs* 13%, $P = 0.03$). However, the fact that there was no significant difference in the outcomes of patients with liver cirrhosis regarding COVID-19 infection is intriguing. It seems important to emphasize that the proportion of SARS-CoV-2-positive cirrhosis patients in this study was approximately three times lower than that in the other two subgroups.

In summary, in patients suffering from COVID-19, mortality is significantly greater in those with liver cirrhosis than in those without and is directly related to the stage of liver failure[18]. However, it remains unclear whether COVID-19-related mortality is higher than that related to other causes of decompensation that are often also infective in origin[18].

Liver cirrhosis causes 2 million deaths globally per year. Prevention of liver decompensation and prompt diagnosis and treatment of cirrhosis-related complications are of the utmost importance[54,55]. Management with endoscopic variceal screening, primary and secondary prophylaxis, implementation of telecommunication and electronic communication in drug titration, especially regarding beta-blockers and diuretic therapies, is warranted. HCC screening and diagnostic persuasion, including radiologic methods and liver biopsy, as well as therapeutic treatments ranging from radiofrequency ablation to liver transplantation (LT), should be preserved despite scarce resources, physician burnout and lack of hospital capacity[54,55].

Tapper and Asrani[55] proposed a three-wave theory to explain the effects of the COVID-19 pandemic on liver cirrhosis from the current period to future years. The first wave describes the period of physical distancing and is defined by high-acuity care and delayed elective procedures[55]. For example, patients with esophageal varices are admitted only for bleeding episodes, and elective endoscopic band ligation (EBL) is not performed due to fear of viral spread and limited healthcare resources. The direct consequence of the first phase is the second wave, appearing after the resolution of physical distancing and characterized by a high frequency of cirrhosis decompensation[55]. Continuing with the given example, a substantial number of patients with indefinitely delayed or skipped EBL procedures will begin to experience variceal bleeding episodes, leading to cirrhosis decompensation or even acute-on-chronic liver failure. Accessible, inexpensive, processed foods rich in salt, as well as alcoholic beverages, both highly consumed during pandemics, will result in the exacerbation of volume overload and also potentiate sarcopenia, which is a well-known risk factor for cirrhosis-associated morbidity and mortality[55]. The third wave will presumably comprise long-term complications. Delayed diagnosis of hepatobiliary malignancies, progression of HCC reaching the Milan criteria and the consequent elimination of patients from transplant lists, insidious deterioration of renal function, no standardized recertification of patients awaiting LT and many more complications are to be encountered. As Tapper and Asrani[55] stated, the curable will be transformed into the incurable.

HCC and COVID-19

Although there are no specific data on the outcomes of patients with HCC and COVID-19 infection, it is assumed that HCC patients will have poor outcomes, similar to those in other oncology patients[15]. However, we know that most HCC patients have pre-existing CLD and in comparison to other patients with cancers we can assume that such patients are more susceptible to the effects of COVID-19: that is, hepatic injury caused by COVID-19 can complicate existing CLD in most patients with HCC. The COVID-19 pandemic has greatly limited the medical care of HCC patients, with effects ranging from early diagnosis to treatment. As ultrasound screening examinations have mostly been delayed indefinitely, without precise upcoming appointment dates and resulting in prolonged periods without control, the risk of discovering HCC at a later stage increased in approximately 25% of patients with the biologically aggressive type of disease[55,56].

Elective hospital admissions were also delayed in the peak of the COVID-19 pandemic due to low hospital capacity and the fear of viral spread. Outpatient ambulatory care was unavailable for a certain time. Subsequently, a substantial number of patients were afraid to visit medical facilities. Therefore, diagnostic procedures such as contrast-enhanced ultrasound, multislice computed tomography, magnetic resonance imaging and liver biopsies have been delayed. Additionally, treatment options have been insufficiently maintained. Surgical resection and LT are the most affected due to a shortage of anesthetists and other medical personnel[6]. Procedures such as transarterial (chemo)embolization (TACE/TAE) and radiofrequency ablation are therefore the most important tools in treating patients with HCC. Data on the impact of COVID-19 on HCC patient care are underrepresented[56,57]. A colleague from an Italian center managed HCC patients with the goal of minimizing the impact of COVID-19 and reported their experience from February 24 to March 20, 2020, regarding the treatment of HCC patients in comparison to the same period during 2019[57]. The authors found that 11% of patients had delayed treatment of HCC for 2 mo or longer. The delayed treatment modalities comprised transarterial procedures in eight HCC patients, thermal ablation in three HCC patients and systemic therapy in two patients. Thermal ablation in the three patients was performed as an alternative procedure to surgical treatment. The results of this study represent the best efforts of clinicians to manage HCC during the COVID-19 pandemic[57].

In the case of early-stage HCC, the capacity of most hospitals for surgical treatment (resection) is limited due to the limited number of anesthesiologists as well as shortages in intensive care unit beds. Clinicians can select some patients who have been prioritized for resection and have a relatively low disease burden. Treatment modalities such as radiofrequency and microwave ablation, upfront transarterial treatment and systemic therapy may be considered as alternative methods according to the guidelines for each treatment modality[56,58]. Additionally, during the pandemic, the number of LTs were reduced or reached zero for some time due to reduced anesthetic capacity as well as a shortage of donors[56,58]. In the case of intermediate-stage HCC, a more selective approach can be used with respect to TACE in hospitals that are greatly affected by the COVID-19 pandemic. Additionally, if a specific center cannot perform TACE, systemic therapy or adequate surveillance, then imaging could be an alternative approach[56,58]. Finally, in the case of advanced-stage HCC, HCC patients who receive oral multitargeted tyrosine kinase inhibitors could be followed by clinicians for prolonged intervals or monitored by telephone or another telemedicine interface, depending on the patient's tolerance and clinical status during the COVID-19 pandemic[56,58]. The impact on the long-term outcomes of HCC due to these modifications in treatment options, as well as the delays in treatment, will soon be realized[57].

The decision to treat HCC during the pandemic should consider the availability of medical staff, risk of infection and the risk-benefit ratio for an individual patient. The management of HCC in patients is complex because it relies heavily on multidisciplinary approaches involving gastroenterologists, radiologists, hepatobiliary surgeons and oncologists, who are significantly burdened during this pandemic[15,56]. Extra coordination among different specialties is necessary to maintain clinical services for patients with HCC. It is recommended that the care and treatment of HCC patients is maintained according to the guidelines by using alternative methods of communication whenever possible in order to minimize the COVID-19 exposure risk to medical staff[15]. Widely available SARS-CoV-2 polymerase chain reaction testing is recommended before elective hospital admission, although there can never be a definite guarantee for medical personnel because a patient may be in the incubation phase of infection or the patient may contract the infection in the hospital. If the patient is acutely infected, it is reasonable to defer HCC treatment for a few weeks until after recovery from COVID-19[6].

LT AND COVID-19

LT programs have been weakened globally, even in regions where the COVID-19 prevalence has been low[59-61]. During this period of readjustment no specific guidelines were offered; however, multiple organizations released recommendations for medical personnel involved in solid organ transplantation[59-66].

Primarily, obtaining an organ from a SARS-CoV-2-infected patient is contraindicated. Moreover, screening of deceased donors, as well as recipients, is highly recommended[59-66]. In the case of unidentified infection, the donor could spread the

virus to multiple recipients, which would presumably have an unfavorable or even lethal course under severe immunosuppression[6,62].

As the risk of contracting the virus is high, even under hospital conditions, it would be appropriate to limit the number of face-to-face contacts for patients at risk of severe COVID-19. They should be advised against travel and should strictly practice physical distancing[6]. Due to cirrhosis-associated immune dysfunction, the aforementioned recommendations apply to all patients awaiting transplantation.

A further challenge is related to the staff involved in LT, who cannot be easily replaced. Quarantined, infected or redistributed personnel can prevent program realization for a certain period of time, which can have deleterious effects on potential LT recipients[59]. Therefore, splitting the team involved in LT and postoperative care into smaller subteams, as well as screening and segregating staff working with immediate post-LT patients, is recommended[59]. Compared to some other solid organ transplantations, LT is performed to preserve life. In contrast, although renal transplantation reduces dialysis morbidity and future medical costs, it is not directly lifesaving and can therefore be postponed[62]. Lifesaving transplantations, such as liver, heart and lung, have far more urgent indications and postponement may have deleterious consequences. Accordingly, it is of utmost importance that LT centers worldwide aim to restore their transplantation services.

Finally, according to preliminary data, age and comorbidity are key to determining the outcome from SARS-CoV-2 infection in LT patients[6,9].

Whether to receive vaccination is currently an unavoidable global question potentiated by substantial social media involvement. Three vaccines were approved by February 2021. Two of these, the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines, are based on mRNAs that encode variants of the SARS-CoV-2-spiked glycoprotein[63]. Both must be administered twice, 21-28 d apart. The third approved vaccine is AZD1222, also known as the Oxford-AstraZeneca vaccine. This is an adenovirus vector that contains the full-length, codon-optimized gene that encodes the SARS-CoV-2 spike protein and should also be administered in two doses, with the second dose administered 4-12 wk after the first dose[63]. The EASL position paper recommends vaccination against SARS-CoV-2 in patients with CLD, hepatobiliary cancer and LT[63].

Post-transplant patients and COVID-19

Patients taking immunosuppressive drugs after transplantation are at increased risk of infection or viral reactivation. The exact influence of the SARS-CoV-2 virus in post-LT patients is unclear[15].

Regarding the disease course in post-transplant patients, it seems that immunosuppression might have favorable effects by disabling cytokine release syndrome, characterized by increased serum levels of interleukin (IL)-6, IL-8 and tumor necrosis factor [15,64]. A Spanish study analyzed 111 LT patients diagnosed with COVID-19[65]. During a median follow-up of approximately 3 wk, 86.5% of patients were admitted to hospital, among which 19.8% required respiratory support[65]. Surprisingly, their mortality rate (18%) was lower than in the complementary general population. Mycophenolate mofetil (MMF) administered at a dose of > 1000 mg/d was an independent predictor of severe COVID-19[65]. In contrast, treatment with calcineurin inhibitors and the mammalian target of rapamycin (mTOR) inhibitor everolimus were not associated with a severe COVID-19 course. Complete withdrawal of immunosuppression showed no benefit[65]. Therefore, MMF withdrawal or transient conversion to calcineurin inhibitors or everolimus could be beneficial for hospitalized patients until the COVID-19 resolves[65].

Vaccination in post-LT patients is recommended at approximately 3-6 mo after transplantation when immunosuppression can be reduced. This is because the immune system is too suppressed to mount the proper vaccination response in the early post-transplant period. Accordingly, vaccination of household members and of health-care professionals caring for immunocompromised patients is advocated[63].

LIVER DISEASE AND COVID-19 IN CHILDREN

A recent review by Di Giorgio *et al*[67] nicely summarizes the current data from 105 studies on the association among pre-existing CLD and COVID-19 infection in children. According to the data, the most common liver manifestation was an elevation of transaminases[67]. The authors found that children with CLD, including those on immunosuppressive therapy (autoimmune liver disease and LT), actually do not have

a higher risk for a severe disease course of COVID-19. Additionally, they have little or no liver dysfunction[67]. As mentioned earlier, we still do not know the exact pathogenetic mechanism of liver damage in either adults or children, therefore we still do not fully understand the clinical outcomes of patients with CLD infected with COVID-19. Furthermore, there are no clear data on infectivity rates in children with CLD or regarding the presence of asymptomatic carriage of the virus in children[67]. Finally, there are no data regarding the long-term outcome of COVID-19 infection in this group of immunocompromised children[67]. Thus, further data are needed.

CURRENT STUDIES AND FUTURE DIRECTIONS

The COVID-19 pandemic has caused serious damage to the global health system and prevented the anticipation, recruitment or completion of numerous clinical trials. However, according to ClinicaTrials.gov, there are currently more than 1500 studies related to 'liver disease' in the recruitment phase[68]. In line with active clinical research and databases including patients with NAFLD and CLD, it is evident that this remains a trending topic, despite the COVID-19 pandemonium. The utilization of noninvasive methods in the assessment of liver and spleen stiffness and indirect prediction of portal hypertension remains the desired goal in the field of CLD. At the same time, clinicians worldwide are determined to find a proper therapy for NAFLD. The effects of glucagon-like peptide agonist (GLP-1) semaglutide, peroxisome proliferator-activated receptor (PPAR) agonist lanifibranor, thiazolidinediones, sodium-glucose cotransporter 2 inhibitors, prebiotics and probiotics are currently being tested in clinical trials[69-73]. Furthermore, the impact of fecal microbiota transplantation on obese patients with NAFLD is being researched on participants in India[74]. A selective thyroid hormone receptor- β agonist, resmetirom (MGL-3196), is in its third trial phase and the mitochondrial-derived peptide (MOTS-c) analog CB4211 is in its 1a/1b phase of evaluation among the NAFLD population[75,76]. Considering the global proportion of obese patients suffering from NAFLD, whose number under the COVID-19-created environment will undoubtedly grow, extension of the mentioned research and anticipation of future studies is encouraged.

CONCLUSION

The global social, economic and political crises related to the COVID-19 pandemic presumably had more indirect than direct negative impacts on health systems. Drastic lifestyle changes, social isolation and distancing, and individual and global financial crises resulted in a robust population forfeiting healthy habits and seeking comfort in alcoholic beverages, drugs and unhealthy diets[19,41]. The inevitable consequences are the rising incidence of NAFLD, viral hepatitis, acute alcoholic hepatitis, liver cirrhosis decompensation and ultimately liver-related mortality[19].

The inaccessibility of regular clinical and sonographic examinations has resulted in difficulties in the treatment of patients with CLD or prompt HCC detection and treatment. A dramatic reduction in the number of liver donors and the transformation of numerous transplantation centers into COVID-19 units have greatly reduced the rate of orthotopic LT.

The indirect unavoidable effects of the COVID-19 pandemic in the following years have yet to be determined[19]. Although the health system has been tremendously challenged, resulting in overwhelming damage that is continuously being revealed, focus should remain on the current and upcoming periods involving patients with uncontrolled chronic diseases[16,19]. Swift resumption of care practices, especially for patients with HCC or individuals requiring LT, must be initiated while simultaneously maintaining social distancing and balancing inadequate hospital resources[16,19].

Substantial efforts should be initiated for the management of patients with liver disease in order to prevent and control the inevitable COVID-19-related morbidity and mortality that will follow.

Several questions regarding the impact of the COVID-19 pandemic on liver disease remain. One of the most important questions is: What will be the effect of long-term anticoagulants on liver disease? The main question for general CLD patients is: How will the modification of clinical practice during this pandemic affect outcomes in CLD patients.

REFERENCES

- 1 **Télez L**, Martín Mateos RM. COVID-19 and liver disease: An update. *Gastroenterol Hepatol* 2020; **43**: 472-480 [PMID: [32727662](#) DOI: [10.1016/j.gastrohep.2020.06.006](#)]
- 2 **Lax SF**, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. *Ann Intern Med* 2020; **173**: 350-361 [PMID: [32422076](#) DOI: [10.7326/M20-2566](#)]
- 3 **Williamson EJ**, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**: 430-436 [PMID: [32640463](#) DOI: [10.1038/s41586-020-2521-4](#)]
- 4 **Nardo AD**, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. *Liver Int* 2021; **41**: 20-32 [PMID: [33190346](#) DOI: [10.1111/liv.14730](#)]
- 5 **Sonzogni A**, Previtali G, Seghezzi M, Grazia Alessio M, Gianatti A, Licini L, Morotti D, Zerbi P, Carsana L, Rossi R, Lauri E, Pellegrinelli A, Nebuloni M. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. *Liver Int* 2020; **40**: 2110-2116 [PMID: [32654359](#) DOI: [10.1111/liv.14601](#)]
- 6 **Wong GL**, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, Yu ML, Piratvisuth T, Chan HL; Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. *Lancet Gastroenterol Hepatol* 2020; **5**: 776-787 [PMID: [32585136](#) DOI: [10.1016/S2468-1253\(20\)30190-4](#)]
- 7 **Cevik M**, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. *Clin Microbiol Infect* 2020; **26**: 842-847 [PMID: [32344166](#) DOI: [10.1016/j.cmi.2020.04.023](#)]
- 8 **Cha MH**, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. *World J Gastroenterol* 2020; **26**: 2323-2332 [PMID: [32476796](#) DOI: [10.3748/wjg.v26.i19.2323](#)]
- 9 **Webb GJ**, Moon AM, Barnes E, Barritt AS 4th, Marjot T. Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. *J Hepatol* 2021; **75**: 226-228 [PMID: [33556419](#) DOI: [10.1016/j.jhep.2021.01.036](#)]
- 10 **Marjot T**, Buescher G, Sebode M, Barnes E, Barritt AS 4th, Armstrong MJ, Baldelli L, Kennedy J, Mercer C, Ozga AK, Casar C, Schramm C; contributing Members and Collaborators of ERN RARE-LIVER/COVID-Hep/SECURE-Cirrhosis, Moon AM, Webb GJ, Lohse AW. SARS-CoV-2 infection in patients with autoimmune hepatitis. *J Hepatol* 2021; **74**: 1335-1343 [PMID: [33508378](#) DOI: [10.1016/j.jhep.2021.01.021](#)]
- 11 **Portincasa P**, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. *Eur J Clin Invest* 2020; **50**: e13338 [PMID: [32589264](#) DOI: [10.1111/eci.13338](#)]
- 12 **Pedersen SF**, Ho YC. SARS-CoV-2: a storm is raging. *J Clin Invest* 2020; **130**: 2202-2205 [PMID: [32217834](#) DOI: [10.1172/JCI137647](#)]
- 13 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: [32192578](#) DOI: [10.1016/S0140-6736\(20\)30628-0](#)]
- 14 **Samarasekera U**. COVID-19 hits viral hepatitis care for vulnerable populations. *Lancet Gastroenterol Hepatol* 2021; **6**: 166 [PMID: [33581759](#) DOI: [10.1016/S2468-1253\(21\)00029-7](#)]
- 15 **Ridruejo E**, Soza A. The liver in times of COVID-19: What hepatologists should know. *Ann Hepatol* 2020; **19**: 353-358 [PMID: [32425991](#) DOI: [10.1016/j.aohep.2020.05.001](#)]
- 16 **Bollipo S**, Kapuria D, Rabiee A, Ben-Yakov G, Lui RN, Lee HW, Kumar G, Siau K, Turnes J, Dhanasekaran R. One world, one pandemic, many guidelines: management of liver diseases during COVID-19. *Gut* 2020; **69**: 1369-1372 [PMID: [32499304](#) DOI: [10.1136/gutjnl-2020-321553](#)]
- 17 **Fix OK**, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. *Hepatology* 2020; **72**: 287-304 [PMID: [32298473](#) DOI: [10.1002/hep.31281](#)]
- 18 **Boettler T**, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Rep* 2020; **2**: 100113 [PMID: [32289115](#) DOI: [10.1016/j.jhepr.2020.100113](#)]
- 19 **Pawlotsky JM**. COVID-19 and the liver-related deaths to come. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 523-525 [PMID: [32528138](#) DOI: [10.1038/s41575-020-0328-2](#)]
- 20 **CDC COVID-19 Response Team**. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 382-386 [PMID: [32240123](#) DOI: [10.15585/mmwr.mm6913e2](#)]
- 21 **Portincasa P**, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-

- 19 infection. Lapping or biting? *Eur J Intern Med* 2020; **77**: 18-24 [PMID: 32507608 DOI: 10.1016/j.ejim.2020.05.035]
- 22 **Lei F**, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Ye P, Xiao B, Mao W, Liu L, Yan Y, Chen G, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology* 2020; **72**: 389-398 [PMID: 32359177 DOI: 10.1002/hep.31301]
- 23 **Feng G**, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, Poucke SV, Liu WY, Zheng MH. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. *J Clin Transl Hepatol* 2020; **8**: 18-24 [PMID: 32274342 DOI: 10.14218/JCTH.2020.00018]
- 24 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: 32283325 DOI: 10.1016/j.cgh.2020.04.002]
- 25 **Richardson S**, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**: 2052-2059 [PMID: 32320003 DOI: 10.1001/jama.2020.6775]
- 26 **Xu L**, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int* 2020; **40**: 998-1004 [PMID: 32170806 DOI: 10.1111/liv.14435]
- 27 **Zhang C**, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; **5**: 428-430 [PMID: 32145190 DOI: 10.1016/S2468-1253(20)30057-1]
- 28 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]
- 29 **Iavarone M**, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagioli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol* 2020; **73**: 1063-1071 [PMID: 32526252 DOI: 10.1016/j.jhep.2020.06.001]
- 30 **Sun J**, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int* 2020; **40**: 1278-1281 [PMID: 32251539 DOI: 10.1111/liv.14470]
- 31 **Docherty AB**, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; **369**: m1985 [PMID: 32444460 DOI: 10.1136/bmj.m1985]
- 32 **Ji D**, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020; **73**: 451-453 [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044]
- 33 **Zhou YJ**, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. *J Hepatol* 2020; **73**: 719-721 [PMID: 32348790 DOI: 10.1016/j.jhep.2020.04.027]
- 34 **Gao F**, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, George J, Zheng MH. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. *J Gastroenterol Hepatol* 2021; **36**: 204-207 [PMID: 32436622 DOI: 10.1111/jgh.15112]
- 35 **Targher G**, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. *Gut* 2020; **69**: 1545-1547 [PMID: 32414813 DOI: 10.1136/gutjnl-2020-321611]
- 36 **Lopez-Mendez I**, Aquino-Matus J, Gall SM, Prieto-Nava JD, Juarez-Hernandez E, Uribe M, Castro-Narro G. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19). *Ann Hepatol* 2021; **20**: 100271 [PMID: 33099028 DOI: 10.1016/j.aohep.2020.09.015]
- 37 **Ferron PJ**, Gicquel T, Mégarbane B, Clément B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? *Biochimie* 2020; **179**: 266-274 [PMID: 32891697 DOI: 10.1016/j.biochi.2020.08.018]
- 38 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]
- 39 **Gao B**, Tsukamoto H. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe? *Gastroenterology* 2016; **150**: 1704-1709 [PMID: 26826669 DOI: 10.1053/j.gastro.2016.01.025]
- 40 **Boeckmans J**, Rodrigues RM, Demuyser T, Piérard D, Vanhaecke T, Rogiers V. COVID-19 and

- drug-induced liver injury: a problem of plenty or a petty point? *Arch Toxicol* 2020; **94**: 1367-1369 [PMID: 32266419 DOI: 10.1007/s00204-020-02734-1]
- 41 **Clemmensen C**, Petersen MB, Sørensen TIA. Will the COVID-19 pandemic worsen the obesity epidemic? *Nat Rev Endocrinol* 2020; **16**: 469-470 [PMID: 32641837 DOI: 10.1038/s41574-020-0387-z]
- 42 **Stanfield D**, Lucey MR. The Heightened Risk of Fatty Liver Disorders in the Time of COVID-19. *Mayo Clin Proc* 2020; **95**: 2580-2581 [PMID: 33276827 DOI: 10.1016/j.mayocp.2020.10.020]
- 43 **Peeraphatdit TB**, Ahn JC, Choi DH, Allen AM, Simonetto DA, Kamath PS, Shah VH. A Cohort Study Examining the Interaction of Alcohol Consumption and Obesity in Hepatic Steatosis and Mortality. *Mayo Clin Proc* 2020; **95**: 2612-2620 [PMID: 33276835 DOI: 10.1016/j.mayocp.2020.04.046]
- 44 **Merli M**, Perricone G, Lauterio A, Prosperi M, Travi G, Roselli E, Petrò L, De Carlis L, Belli L, Puoti M. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. *Liver Transpl* 2020; **26**: 1543-1544 [PMID: 32475054 DOI: 10.1002/lt.25806]
- 45 **Da BL**, Im GY, Schiano TD. Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease. *Hepatology* 2020; **72**: 1102-1108 [PMID: 32369624 DOI: 10.1002/hep.31307]
- 46 **Wiśniewska H**, Skowron M, Bander D, Hornung M, Jurczyk K, Karpińska E, Laurans Ł, Socha Ł, Czajkowski Z, Wawrzynowicz-Syczewska M. Nosocomial COVID-19 Infection and Severe COVID-19 Pneumonia in Patients Hospitalized for Alcoholic Liver Disease: A Case Report. *Am J Case Rep* 2020; **21**: e927452 [PMID: 32973125 DOI: 10.12659/AJCR.927452]
- 47 **Kapur D**, Upadhyay S, Shekhar R, Torrazza-Perez E. Alcoholic Liver Disease and COVID-19 Pneumonia: A Case Series. *J Clin Transl Hepatol* 2020; **8**: 463-466 [PMID: 33447531 DOI: 10.14218/JCTH.2020.00053]
- 48 **Karimi-Sari H**, Rezaee-Zavareh MS. COVID-19 and viral hepatitis elimination programs: Are we stepping backward? *Liver Int* 2020; **40**: 2042 [PMID: 32319207 DOI: 10.1111/liv.14486]
- 49 **Blach S**, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, Razavi H, Waked I, Zeuzem S, Craxi A. Impact of COVID-19 on global HCV elimination efforts. *J Hepatol* 2021; **74**: 31-36 [PMID: 32777322 DOI: 10.1016/j.jhep.2020.07.042]
- 50 **Moon AM**, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genesca J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. *J Hepatol* 2020; **73**: 705-708 [PMID: 32446714 DOI: 10.1016/j.jhep.2020.05.013]
- 51 **Hunt RH**, East JE, Lanas A, Malfertheiner P, Satsangi J, Scarpignato C, Webb GJ. COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. *Dig Dis* 2021; **39**: 119-139 [PMID: 33040064 DOI: 10.1159/000512152]
- 52 **Marjot T**, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. *J Hepatol* 2021; **74**: 567-577 [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024]
- 53 **Singh S**, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. *Gastroenterology* 2020; **159**: 768-771.e3 [PMID: 32376408 DOI: 10.1053/j.gastro.2020.04.064]
- 54 **Asrani SK**, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019; **70**: 151-171 [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014]
- 55 **Tapper EB**, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. *J Hepatol* 2020; **73**: 441-445 [PMID: 32298769 DOI: 10.1016/j.jhep.2020.04.005]
- 56 **Chan SL**, Kudo M. Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. *Liver Cancer* 2020; **9**: 491-502 [PMID: 33078127 DOI: 10.1159/000510765]
- 57 **Iavarone M**, Sangiovanni A, Carrafiello G, Rossi G, Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. *Ann Oncol* 2020; **31**: 1084-1085 [PMID: 32330540 DOI: 10.1016/j.annonc.2020.04.007]
- 58 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]
- 59 **Niriella MA**, Siriwardana RC, Perera MTPR, Narasimhan G, Chan SC, Dassanayake AS. Challenges for Liver Transplantation During Recovery From the COVID-19 Pandemic: Insights and Recommendations. *Transplant Proc* 2020; **52**: 2601-2606 [PMID: 32586665 DOI: 10.1016/j.transproceed.2020.05.032]
- 60 **Di Maira T**, Berenguer M. COVID-19 and liver transplantation. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 526-528 [PMID: 32651555 DOI: 10.1038/s41575-020-0347-z]
- 61 **Ritschl PV**, Nevermann N, Wiering L, Wu HH, Moroder P, Brandl A, Hillebrandt K, Tacke F, Friedersdorff F, Schlomm T, Schöning W, Öllinger R, Schmelzle M, Pratschke J. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. *Am J Transplant* 2020; **20**: 1826-1836 [PMID: 32323460 DOI: 10.1111/ajt.15933]

- 62 **Kumar D**, Manuel O, Natori Y, Egawa H, Grossi P, Han SH, Fernández-Ruiz M, Humar A. COVID-19: A global transplant perspective on successfully navigating a pandemic. *Am J Transplant* 2020; **20**: 1773-1779 [PMID: 32202064 DOI: 10.1111/ajt.15876]
- 63 **Cornberg M**, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. *J Hepatol* 2021; **74**: 944-951 [PMID: 33563499 DOI: 10.1016/j.jhep.2021.01.032]
- 64 **D'Antiga L**. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. *Liver Transpl* 2020; **26**: 832-834 [PMID: 32196933 DOI: 10.1002/lt.25756]
- 65 **Colmenero J**, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuño J, Gastaca M, Bustamante-Schneider J, Cachero A, Lladó L, Caballero A, Fernández-Yunquera A, Loinaz C, Fernández I, Fondevila C, Navasa M, Iñarrairaegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Noguera F, Otero A, Álamo JM, Blanco-Fernández G, Fábrega E, García-Pajares F, Montero JL, Tomé S, De la Rosa G, Pons JA. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. *J Hepatol* 2021; **74**: 148-155 [PMID: 32750442 DOI: 10.1016/j.jhep.2020.07.040]
- 66 **Qin J**, Wang H, Qin X, Zhang P, Zhu L, Cai J, Yuan Y, Li H. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology* 2020; **72**: 1491-1493 [PMID: 32220017 DOI: 10.1002/hep.31257]
- 67 **Di Giorgio A**, Hartleif S, Warner S, Kelly D. COVID-19 in Children With Liver Disease. *Front Pediatr* 2021; **9**: 616381 [PMID: 33777864 DOI: 10.3389/fped.2021.616381]
- 68 **U.S. National Library of Medicine**. Identifier NCT00287391. [cited 27 Feb 2021]. In: ClinicalTrials.gov [Internet]. 2000 Feb 29 - . [about 15 screens]. Available from: URL: https://clinicaltrials.gov/ct2/results?cond=liver+disease&Search=Apply&recrs=a&age_v=&gndr=&type=&rslt=
- 69 **Erlanson K**, Lake JE. Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study). [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Birmingham (AL): U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT04216589?recrs=a&cond=liver+disease&draw=3&rank=58> ClinicalTrials.gov Identifier: NCT04216589
- 70 **Rotman Y**. Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES). [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT03884075?recrs=a&cond=liver+disease&draw=3&rank=44> ClinicalTrials.gov Identifier: NCT03884075
- 71 **Cha BS**. Comparison of The Effects of Thiazolidinediones (TZD), Sodium- Glucose Cotransporter 2 Inhibitors (SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Seoul: U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT03646292?recrs=a&cond=liver+disease&draw=3&rank=47> ClinicalTrials.gov Identifier: NCT03646292
- 72 **Ahuja K**, Sheflin-Findling S. Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. New Hyde Park (NY): U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT04671186?recrs=a&cond=liver+disease&draw=3&rank=60> ClinicalTrials.gov Identifier: NCT04671186
- 73 **Cusi K**. Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Gainesville (FL): U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT03459079?recrs=a&cond=liver+disease&draw=3&rank=53> ClinicalTrials.gov Identifier: NCT03459079
- 74 **Kar PS**. Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. New Delhi: U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT04594954?recrs=a&cond=liver+disease&draw=3&rank=26> ClinicalTrials.gov Identifier: NCT04594954
- 75 **Taub R**. A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients (MAESTRO-NAFLD1). [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Birmingham (AL): U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT04197479?recrs=a&cond=liver+disease&draw=3&rank=24> ClinicalTrials.gov Identifier: NCT04197479
- 76 **CohBar, Inc**. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. [accessed 2021 Feb 27]. In: ClinicalTrials.gov [Internet]. Chula Vista (CA): U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT03998514?recrs=a&cond=liver+disease&draw=3> ClinicalTrials.gov Identifier: NCT03998514



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

